Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.63 |
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | MMP12 | P39900 | 1/20 | 0.57 |
| ▸ | PARP1 | P09874 | 1/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | CASP3 | P42574 | 1/20 | 0.54 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29901720 | 1.00 | ALDH1A1 (0.63) | ALDH1A1MAPTGAAPOLBPKM | |
| SCHEMBL29978611 | 0.89 | ALDH1A1 (0.52) | ALDH1A1MAPTGAAPOLBPKM | |
| SCHEMBL303909 | 0.89 | ALDH1A1 (0.52) | ALDH1A1MAPTGAAPOLBPKM | |
| SCHEMBL15964647 | 0.86 | ALOX5 (0.54) | ALDH1A1MAPTGAAPOLBPKM | |
| SCHEMBL4265304 | 0.86 | ALDH1A1 (0.57) | ALDH1A1MAPTGAAPOLBPKM | |
| SCHEMBL13932092 | 0.86 | ALDH1A1 (0.57) | ALDH1A1MAPTGAAPOLBPKM | |
| SCHEMBL19691246 | 0.85 | GAA (0.65) | ALDH1A1MAPTGAAPOLBPKM | |
| SCHEMBL2954111 | 0.85 | MAPT (0.62) | ALDH1A1MAPTGAAPOLBPKM | |
| SCHEMBL352186 | 0.84 | ALDH1A1 (0.68) | ALDH1A1MAPTGAAPOLBPKM | |
| SCHEMBL9369062 | 0.83 | MAPT (0.46) | ALDH1A1MAPTGAAPOLBPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355683-A1 | QUINAZOLINE HETEROCYCLIC COMPOUND AS EGFR KINASE INHIBITOR AND PREPARATION AND APPLICATION THEREOF | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2017-12-14 | — | — | US | claimed |
| EP-3246328-A1 | QUINAZOLINE HETEROCYCLIC COMPOUND AS EGFR KINASE INHIBITOR, AND PREPARATION AND APPLICATION THEREOF | Beijing Scitech-MQ Pharmaceuticals Limited (CN) | 2017-11-22 | — | — | EP | claimed |
| EP-4081521-B1 | SUBSTITUTED TRICYCLIC COMPOUNDS | LUPIN LTD (IN) | 2025-12-10 | — | — | EP | disclosed |
| CN-115605476-B | Substituted tricyclic compounds | 鲁宾有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20230406830-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | Valo Health, LLC | 2023-12-21 | — | — | US | disclosed |
| WO-2023165438-A1 | TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 浙江海正药业股份有限公司 | 2023-09-07 | — | — | WO | disclosed |
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230119316-A1 | Substituted Tricyclic Compounds | LUPIN LIMITED (IN) | 2023-04-20 | — | — | US | disclosed |
| CN-115605476-A | Substituted tricyclic compounds | 鲁宾有限公司（IN） | 2023-01-13 | — | — | CN | disclosed |
| WO-2023280317-A1 | BENZYLAMINO TRICYCLIC COMPOUND AND USE THEREOF | 南京明德新药研发有限公司 | 2023-01-12 | — | — | WO | disclosed |
| EP-1531813-A1 | USE OF COMPOUNDS FOR INCREASING SPERMATOZOA MOTILITY | Applied Research Systems ARS Holding N.V. (AN) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004006916-A1 | USE OF COMPOUNDS FOR INCREASING SPERMATOZOA MOTILITY | APPLIED RESEARCH SYSTEMS ARS HOLDING NV (AN) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004007491-A1 | AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2004-01-22 | — | — | WO | disclosed |
| EP-0816348-B1 | Heterocyclic n-acetonylbenzamides and their use as fungicides | DOW AGROSCIENCES LLC (US) | 2003-02-05 | — | — | EP | disclosed |
| EP-1229028-A1 | Heterocyclic N-acetonylbenzamides and their use as fungicides | Dow AgroSciences LLC (US) | 2002-08-07 | — | — | EP | disclosed |
| EP-1229037-A1 | Heterocyclic N-acetonylbenzamides and their use as fungicides | Dow AgroSciences LLC (US) | 2002-08-07 | — | — | EP | disclosed |
| EP-1229027-A1 | Heterocyclic N-acetonylbenzamides and their use as fungicides | Dow AgroSciences LLC (US) | 2002-08-07 | — | — | EP | disclosed |
| US-5811427-A | FUNGICIDES; CONTROLLING PHYTOPATHOGENIC FUNGI PARTICULARLY OF THE CLASS OOMYCETES | ROHM AND HAAS COMPANY (US) | 1998-09-22 | — | — | US | disclosed |
| EP-0816348-A1 | Heterocyclic n-acetonylbenzamides and their use as fungicides | ROHM AND HAAS COMPANY (US) | 1998-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | BCL6, SOX18, BCL3 | ALDH1A1 2654/4885MAPT 4492/4885GAA 2210/4885 |
| US-20230406830-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | HDAC8, HDAC3, HDAC2 | ALDH1A1 1338/4885MAPT 135/4885GAA 741/4885 |
| US-20170355683-A1 | QUINAZOLINE HETEROCYCLIC COMPOUND AS EGFR KINASE INHIBITOR AND PREPARATION AND APPLICATION THEREOF | EGFR, ERBB2, ERBB4 | ALDH1A1 2176/4885MAPT 4419/4885GAA 1729/4885 |
| US-20230119316-A1 | Substituted Tricyclic Compounds | SOS1, RSU1, KSR1 | ALDH1A1 3322/4885MAPT 157/4885GAA 2659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.